Biogen BIIB and partner Eisai announced that the European Commission (EC) has granted marketing authorization to Leqembi (lecanemab) for early Alzheimer’s disease (AD). The regulatory body has ...

Eisai and Biogen get another chance. Read why the latest from the two companies is a big step forward even though it's still just a glimmer of hope for Alzheimer’s sufferers.

Biogen, Eisai, and all other drug companies seeking FDA accelerated approval for a class of Alzheimer's drugs known as monoclonal antibodies would fall under Medicare's decision to pay for the ...

Eisai and Biogen's drug, sold under the brand name Leqembi, is the first amyloid-targeting medication to pass the FDA's full review. Hotspots ranked Start the day smarter ...

Nine months after the U.S. launch of Eisai Limited (OTC:ESALY) and Biogen Inc’s (NASDAQ:BIIB) Leqembi, the first drug shown to slow Alzheimer’s progression, adoption faces hurdles due to ...

Biogen and Eisai will now co-promote Biogen’s multiple sclerosis (MS) treatments, AVONEX ® (interferon beta 1a), TYSABRI ® (natalizumab), and TECFIDERA ® (dimethyl fumarate) in Japan to ...

CAMBRIDGE, Mass., March 21, 2019-- Biogen and Eisai, Co., Ltd. today announced the decision to discontinue the global Phase 3 trials, ENGAGE and.

ICARE AD-US is an observational real-world phase 4 study designed to evaluate the safety and effectiveness of ADUHELM in clinical practice ICARE AD-US is one of three programs to generate post ...

Drugmakers Eisai and Biogen presented positive results of their much-anticipated experimental Alzheimer’s drug BAN-2401 today at the Alzheimer’s Association International Conference in Chicago.

Biogen and Eisai also plan to submit the drug for full approval by the end of March. Advertisement Brian Skorney, an analyst at the investment bank Baird said the results of the lecanemab trial ...

Drugmakers Biogen and Eisai said the top dose of an experimental Alzheimer's drug slowed deadly brain-destroying disease over the course of 18 months in patients in the milder, ...

Once again, Eisai and Biogen are touting success for an anti-amyloid drug that has limited efficacy combined with safety issues.The first and most important point to make about lecanemab (formerly ...